Rigel Pharmaceuticals Inc - logo

Rigel Pharmaceuticals Inc - Company & Market Research Reports

Rigel Pharmaceuticals is a clinical-stage biotechnology company that focuses on the therapeutic areas of immunology, oncology and immuno-oncology. Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of a variety of diseases. It has been in trials for rheumatoid arthritis, autoimmune thrombocytopenia, lymphoma and others. In addition, Rigel also has two oncology product candidates in development. Founded in 1996, Rigel is headquartered in San Francisco, California.


Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H1 2018 - Product Thumbnail Image

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H1 2018

  • Report
  • 47 Pages
From
Gouty Arthritis (Gout) - Pipeline Review, H1 2018 - Product Thumbnail Image

Gouty Arthritis (Gout) - Pipeline Review, H1 2018

  • Report
  • 99 Pages
From
Janus Kinase (JAK) Inhibitor -Pipeline Insight, 2018 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitor -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Competitor Analysis: Janus Kinase (JAK) Inhibitors - Product Thumbnail Image

Competitor Analysis: Janus Kinase (JAK) Inhibitors

  • Report
  • 44 Pages
From
Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs - Product Thumbnail Image

Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs

  • Report
  • 126 Pages
From
Psoriatic Arthritis - Pipeline Review, H1 2018 - Product Thumbnail Image

Psoriatic Arthritis - Pipeline Review, H1 2018

  • Report
  • 241 Pages
From
Asthma Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Asthma Therapeutics - Global Strategic Business Report

  • Report
  • 383 Pages
From
Thrombocytopenia - Market Insights, Epidemiology and Market Forecast-2027 - Product Thumbnail Image

Thrombocytopenia - Market Insights, Epidemiology and Market Forecast-2027

  • Drug Pipelines
  • 240 Pages
From
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2018 - Product Thumbnail Image

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2018

  • Report
  • 116 Pages
From
Thrombocytopenia - Pipeline Review, H2 2016 - Product Thumbnail Image

Thrombocytopenia - Pipeline Review, H2 2016

  • Report
  • 163 Pages
From
OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025 - Product Thumbnail Image

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025

  • Drug Pipelines
  • 243 Pages
From
Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2018 - Product Thumbnail Image

Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Thrombocytopenia - Pipeline Review, H1 2016 - Product Thumbnail Image

Thrombocytopenia - Pipeline Review, H1 2016

  • Report
  • 178 Pages
From
Thrombocytopenia - Pipeline Review, H1 2015 - Product Thumbnail Image

Thrombocytopenia - Pipeline Review, H1 2015

  • Report
  • 188 Pages
From
IgA Nephropathy Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments - Product Thumbnail Image

IgA Nephropathy Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

  • Report
  • 97 Pages
From
Rheumatoid Arthritis: Beyond TNF Inhibitors, 2016-2026 - Product Thumbnail Image

Rheumatoid Arthritis: Beyond TNF Inhibitors, 2016-2026

  • Report
  • 240 Pages
From
Rheumatoid Arthritis Market to 2020 - A Crowded Market Characterized by Modest Growth - Product Thumbnail Image

Rheumatoid Arthritis Market to 2020 - A Crowded Market Characterized by Modest Growth

  • Report
  • 139 Pages
From
Interleukin-4 (IL-4) Inhibitor -Pipeline Insight, 2018 - Product Thumbnail Image

Interleukin-4 (IL-4) Inhibitor -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Interleukin-13 (IL-13) Inhibitor -Pipeline Insight, 2018 - Product Thumbnail Image

Interleukin-13 (IL-13) Inhibitor -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module - Product Thumbnail Image

Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module

  • Report
  • 133 Pages
From
Loading Indicator
adroll